GAIA-102 is under clinical development by GAiA BioMedicine and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GAIA-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GAIA-102 is under development for the treatment of ovarian cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, rhabdomyosarcoma, undifferentiated sarcoma, Ewing's sarcoma, osteosarcoma, other cartilage sarcoma, nephroblastoma, hepatoblastoma and germ cell neoplasma and neuroblastoma. The drug candidate comprise of highly activated and expanded natural killer cells. It is administered intravenous and intraperitoneal routes of administration.
GAiA BioMedicine overview
GAiA BioMedicine, is a developer of a biopharmaceutical company intended to deliver new therapeutic agents that specializes in cell therapies and immunotherapies. The company is headquartered in Japan.
For a complete picture of GAIA-102’s drug-specific PTSR and LoA scores, buy the report here.